1338220-75-9

Upstream product

• 549503-20-0 5-(p-tert-butyldimethylsilyloxyphenyl)-2-amino-1,4-pyrazine 
• 159191-56-7 (4-((tert-butyldimethylsilyl)oxy)phenyl)boronic acid 
• 106-41-2 4-bromo-phenol 
• 1178890-01-1 2-amino-3-bromo-5-[p-(t-butyldimethylsilyloxy)phenyl]-1,4-pyrazine 
• 13922-41-3 1-Naphthylboronic acid 
• 67963-68-2 t-butyldimethylsilyl-4-bromophenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1338220-95-3 2-[4-(tert-butyldimethylsilyloxy)phenyl]-N-[5-{4-(tert-butyldimethyl silyloxy)phenyl}-3-(naphthalen-1-yl)pyrazin-2-yl]acetamide 
• 1338220-29-3 2-(4-hydroxyphenyl)-N-[5-(4-hydroxyphenyl)-3-(naphthalen-1-yl)pyrazin-2-yl]acetamide 
• 1338220-11-3 2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)-8-(naphthalen-1-yl)imidazo[1,2-a]pyrazin-3(7H)-one 

Relevant academic research and scientific papers

COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES

Coelenterazine analogs with different luminescence properties from conventional ones and coelenteramide analogs with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogs modified at the

COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES

Coelenterazine analogues with different luminescence properties from conventional ones and coelenteramide analogues with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogues modified at the 8-position of coelenterazine and coelenteramide analogues modified at the 2- or 3-position of coelenteramide.